Rubius Therapeutics Stock Price, News & Analysis
Company Description
Rubius Therapeutics (OTC: RUBY) is a publicly traded research and development in biotechnology company in the Professional, Scientific, and Technical Services sector.
RUBY stock has declined 100.0% over the past year.
This page provides a comprehensive overview of RUBY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Rubius Therapeutics (RUBY) stock. Over the past 12 months, the stock has lost 100.0%.
Latest News
Rubius Therapeutics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. Key topics include management, conferences, earnings. View all RUBY news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
RUBY Company Profile & Sector Positioning
Rubius Therapeutics (RUBY) operates in the Research and Development in Biotechnology industry within the broader Professional, Scientific, and Technical Services sector and is listed on the OTC.